Editorial N ADPH oxidases of the Nox family are important sources of reactive oxygen species (ROS). Nox-derived ROS serve multiple functions in the organism, but in the healthy vascular system they are primarily signaling molecules. Numerous cytokines, growth factors, and hormones have been shown to stimulate Nox-dependent ROS production as essential step in their signal transduction. 1 Seven catalytically active Nox proteins are present in the human genome. In the vascular system, the constitutively active Nox4 provides a basal redox tone to tune the antioxidant defense, 2 whereas Nox1, Nox2, and Nox5 contribute to the stimulus-dependent acute ROS production. There are still uncertainties on the cell-specific expression patterns of these proteins and particularly little is known about Nox5, which it is missing in the rodent genome. Despite this, it is generally accepted that endothelial cells predominantly express Nox2, whereas in smooth muscle cells of greater arteries, mainly Nox1 is expressed. In resistance vessels and also in response to vascular stress, Nox1 and Nox2 are expressed throughout the vessel. 
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The activity control of Nox enzymes differs between the homologues. For Nox1 and Nox2, it is primarily a consequence of protein-protein interactions. The general concept is that upstream signaling cascades converge to the small GTPase Rac1 and to the phosphorylation of the cytosolic organizing protein p47phox. On phosphorylation, p47phox binds to the plasma membrane and also binds to the activating proteins: Noxa1 or p67phox. The consequence of this is a translocation of the activating protein to the large transmembrane catalytically active Nox protein, which is thereby activated 4 ( Figure 1 ). In this issue of Circulation Research, Streeter et al 5 report a totally novel mechanism controlling the activity of Nox1, which is phosphorylation by protein kinase C beta (PKCβ). The authors demonstrate that this event is also relevant for oxidative stress in vivo. In atherosclerosis, during neointima formation and in response to inflammatory cytokines, Nox1 becomes phosphorylated and active. Subsequent mass spec analyses and mutational studies led to the identification of the critical importance of threonine 429 in this process. The authors confirm previous work that interaction of Nox1 with cytosolic proteins is a prerequisite for Nox1 activation, 6,7 but without Nox1 T429 phosphorylation this interaction cannot occur and stimuli, such as tumor necrosis factor α, plateletderived growth factor, and angiotensin II, therefore fail to activate Nox1. Accordingly, the nonphosphorylatable Nox1 mutant T429A failed to produce ROS, whereas the phosphomimetic T429D had an activity similar to the wild-type enzyme. Interestingly, the response to phorbol ester, which leads to a massive activation of the enzyme, was independent of the phosphorylation state of T429, suggesting that the mechanism uncovered by Streeter et al 5 is central for physiological signal but can be overcome under certain conditions.
The fact that Nox1 activity is controlled by PKC-mediated phosphorylation on T429 is important for several reasons: The phosphorylation site seems to be unique among the Nox enzymes and the modeling performed by Streeter et al 5 suggests that at least on the peptide basis this knowledge can be used for inhibitor development. Indeed, a peptide containing the Nox1 interaction site of Noxa1 has been developed by Ranayhossaini et al 8 and turned out to be highly selective and efficient already in the nanomolar range. The study by Streeter et al 5 also helps to explain why PKC inhibition is so effective in lowering vascular oxidative stress. In the standard model of Nox activation, AKT and p21-protein activated kinase are discussed as additional upstream activators of Nox enzymes. These kinases can phosphorylate p47phox on multiple serines just as protein kinase C does. 4 In contrast to this, the Nox1 T429 phosphorylation seems to be PKC specific. Finally, we still know little about the contribution of the different cytosolic proteins to Nox activation. For the present work, Noxo1 is particularly relevant. This protein lacks the autoinhibitory region of p47phox and thus overexpression of Nox1 together with Noxo1 and Noxa1 results in constitutive ROS production. It can be speculated that by T429 phosphorylation of Nox1 this ROS formation is modulated. 6, 7 The concept is attractive as in situations of oxidative stress, Nox enzymes switch from acute agonist-stimulated ROS production to a continuous mode with high ROS output, which eventually results in oxidative stress. Importantly, Streeter et al 5 report that in such conditions, Nox1 is constitutively phosphorylated on T429 5 and it was previously realized that inhibition of PKC lowers the chronic Nox1-dependent ROS production present in angiotensin II-induced hypertension 9 and diabetes mellitus. 10 It is fascinating to experience that within a few years, tremendous progress has been made in identifying molecular mechanisms of Nox biology. Numerous phosphorylation switches have been identified ( Figure 2 ) and a complex downstream redox-network has been unraveled. Despite all this work, the somewhat teleological question on the true function of Nox enzymes remains open. Of the 7 proteins, only 3 are essential: Nox3 is required for otolite formation in the ear, Duox2 for thyroid hormone production, and Nox2 for host defense by polymorph nuclear neutrophils. Nox1 shares many similarities with Nox2 and potentially arose by gene duplication. Nox1 is most highly expressed in epithelial cells, particularly in the gut. 13 This may suggest that it contributes to the maintenance of intestinal barrier integrity and thus to host defense, but few studies support this view. Nox1 is induced by cytokines and functional significant, yet low expression has been observed throughout the body. Previous work from Miller et al 14 on smooth muscle Nox1 convincingly demonstrated that the enzyme contributes to endosomal inflammatory signaling. Thus, it seems that Nox1 is a facilitator of the inflammatory response and indeed for Nox1, but not for Nox2 or Nox4, a significant contribution to atherosclerosis development in mouse models has been established. 15 This makes Nox1 a potential cardiovascular drug target, but except for peptide inhibitor of Dr Pagano 8 no small molecule compounds that specifically inhibit Nox1 have been developed. Such inhibitors are urgently needed and it is to be hoped that a suitable compound will arise from the numerous initiatives currently searching for Nox inhibitors. Only then we will learn about the true importance of Nox1 for the human vascular system. indicates that the presence of the protein is unclear; AngII, angiotensin II; bFGF, basic fibroblast growth factor; PDGF, platelet-derived growth factor; TLR, Toll-like receptor; and TNF, tumor necrosis factor.
